Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation'

Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia

June 20, 2024 8:05 AM EDT

ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally

Novel transdermal formulation of ALTO-101 exhibited favorable pharmacokinetics and tolerability, greater drug exposure, and fewer PDE4 associated adverse events compared to ALTO-101 administered orally

LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (Alto)... More

Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner

June 18, 2024 8:05 AM EDT

Dr. Etkin recognized as a Bay Area winner out of 26 finalists by an independent panel of judges

Entrepreneur Of The Year celebrates ambitious entrepreneurs who are shaping the future across all industries

LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (Alto) (NYSE:... More